Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority

Risankizumab, an anti‐interleukin‐23 monoclonal antibody, achieved significantly (P < 0.001) greater Psoriasis Area and Severity Index (PASI) and static Physician Global Assessment (sPGA) clear or almost clear (0/1) responses than adalimumab in a phase III trial in patients with moderate‐to‐sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Witjes, Han, Khatri, Amit, Diderichsen, Paul M., Mandema, Jaap, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006886/
https://www.ncbi.nlm.nih.gov/pubmed/31502263
http://dx.doi.org/10.1002/cpt.1624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006886/
https://www.ncbi.nlm.nih.gov/pubmed/31502263
http://dx.doi.org/10.1002/cpt.1624

Ejemplares similares